A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

NCT07717905 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: BBT001
DRUG: Placebo

Sponsor

Bambusa Therapeutics